• Research, Science, and Trials

  Skyclarys is now approved in Canada!

  Posted by Christina on March 24, 2025 at 8:30 am

  Did you hear the great news? Biogen Canada Inc. announced that Health Canada has approved Skyclayrs (omaveloxolone) for treating Friedreich’s ataxia (FA) in patients.

  It is great to see that the approval of the treatment is being approved beyond the United States. Like the U.S., Canada is committed to advancing treatment options for rare diseases, such as FA.

  Do you feel hopeful that the only approved treatment for FA will keep expanding to other countries?

  For the press release, please click below:

  https://www.biogen.ca/en-ca/news/2025-03-17-news.html

  

  biogen.ca

  SKYCLARYS™ (omaveloxolone) Approval by Health Canada Ushers in a New Era for Friedreich’s Ataxia Treatment in Canada

  Biogen Canada is pleased to announce that Health Canada has approved SKYCLARYS™ (omaveloxolone) for the treatment of Friedreich’s ataxia (FA) in patients 16 years of age and older.

  Christina replied 1 month, 3 weeks ago 1 Member · 0 Replies

  • press release
  • skyclarys
  • treatment
• 0 Replies

Log In to Reply